Medical products, interventions and clinical trials highlights
Medical products, interventions and clinical trials (Outputs highlight)
Researchers supported via the MRC’s prevention portfolio (awards active since 2006) gave rise to 12 per cent of all medical products reported despite this portfolio only representing five per cent of MRC awards. This highlights the focus this extremely translational portfolio has on developing new interventions. A total of 153 medical products or clinical trials (33 from the NPRI awards) have been reported as outcomes of MRC-funded research. These products are predominantly classed in four medical product types (see Figure 12), with 80 per cent of all products reported across the total MRC portfolio categorised as ‘Preventative – physical/behaviour risk modification’ are attributed to prevention awards (49 of 62 total, 19 from NPRI awards). It is perhaps not surprising that the majority of products aimed at disease prevention are being developed by projects in the prevention portfolio.
In addition, products reported from the prevention portfolio include a number of interventions with a specific demographic or geographical focus, including:
- ‘Shape Up Sister’ promoting regular exercise among black women in London
- ‘Life Lab’ aimed at school children to widen health literacy and awareness of long term health behaviours
- ‘Southampton initiative for health’ changing health perspectives for families attending Sure Start Children Centres in Southampton
- An intervention specific to smokeless tobacco users, favoured by South Asian communities.
Such bespoke studies, developed to focus on specific sociological groups, can lead to improved outcomes where standardised interventions are potentially less effective.